Filling in the Treatment Gap for Patients With EGFR+ NSCLC

April 9, 2021
Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.

Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas discusses the limited treatment options available for patients with non–small cell lung cancer (NSCLC) and an EGFR exon 20 mutation.

There is currently no FDA approved agent to treat patients with EGFR or HER2 exon 20-positive NSCLC. Targeting these oncogenes is a great unmet medical need, explains Le, and although chemotherapy is still an option to treat patients with EGFR-positive NSCLC, it is important use all the tools that are available to treat this patient population.

Introducing a small molecule tyrosine kinase inhibitor such as poziotinib is important for the future treatment of EGFR and HER exon 20-positive NSCLC. The hope is to bring more options to field.